Anaphylaxis market seen topping $5.14 billion by 2030

The global anaphylaxis market is projected to rise from $3.5 billion in 2025 to $5.14 billion by 2030, driven by more food and drug allergies, faster diagnosis and wider use of emergency epinephrine treatments. North America led the market in 2025, while Asia-Pacific and Southeast Asia are expected to grow fastest.

Why it matters: - The anaphylaxis market is tied to the growing burden of life-threatening allergic reactions. - Higher demand for emergency epinephrine and better access to allergy care can affect treatment speed, patient outcomes and healthcare spending. - Rising food allergy cases are expanding the need for diagnosis, monitoring and emergency preparedness.

What happened: - The Business Research Company projected the global anaphylaxis market will grow from $3.5 billion in 2025 to $3.79 billion in 2026. - The market is forecast to reach $5.14 billion by 2030, implying a 7.9% compound annual growth rate from 2026 to 2030. - The report was released Oct. 30, 2026, as part of the company’s Anaphylaxis Global Market Report 2026. - The company also published a free sample report and the full market report online: Download the sample report and View the full report.

The details: - Historical growth has been supported by more food and drug allergy cases, better diagnosis, broader availability of emergency epinephrine treatments, greater public health awareness and standardized clinical guidelines. - Forecast growth is linked to improved access to emergency allergy care, rising demand for portable treatment devices, expanding allergy specialty services, stronger patient education and more investment in allergy management infrastructure. - Key trends include wider availability of epinephrine auto-injectors, greater awareness of severe allergic reactions, stronger emergency preparedness, better allergy diagnosis and monitoring, and faster response protocols. - Anaphylaxis is a fast-moving, life-threatening allergic reaction that can cause breathing difficulty, swelling and a dangerous drop in blood pressure. - Treatment centers on prompt epinephrine administration, followed by close observation in a healthcare setting. - Food allergies remain a major growth driver because they can trigger severe reactions that require immediate treatment. - The World Health Organization reported in September 2024 that about 220 million people globally suffer from food allergies. - The Food Standards Agency reported in May 2024 that more than 30% of adults experienced food-related adverse reactions, and about 6% of UK adults, or around 2.4 million people, were confirmed through clinical assessment to have food allergies.

Between the lines: - The market outlook suggests allergy care is shifting from emergency-only treatment toward broader systems for prevention, rapid diagnosis and preparedness. - The emphasis on portable devices and rapid response protocols points to continued demand for consumer-facing and point-of-care solutions. - North America’s lead reflects mature healthcare infrastructure and established treatment access, while faster growth in Asia-Pacific and Southeast Asia signals room for market expansion in regions still building allergy awareness and care pathways.

What's next: - The report expects continued growth as healthcare systems expand access to emergency allergy treatment and patient education. - Asia-Pacific and Southeast Asia are projected to post the fastest growth rates in the coming years. - The Business Research Company said its 2026 reports now include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, and updated trend analysis. - The company listed contact information for expert inquiries and promotional follow-up, including Saumya Sahay at marketing@tbrc.info and its social media channels.

The bottom line: - Rising allergy prevalence is keeping the anaphylaxis market on a steady growth path, with emergency treatment access and portable care tools likely to remain the main commercial drivers.